跳至主要内容
临床试验/IRCT20190714044199N1
IRCT20190714044199N1招募中3 期

Evaluating the efficacy of adding N-Acetyl cysteine to risperidone treatment regimen in patients with autism spectrum disorder

Medical Science University of Mashhad0 个研究点目标入组 66 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
3 years 至 12 years(—)
性别
All

入选标准

  • Autism spectrum disorder (ASD) patients aging between 3 to 12
  • Having parental informed consent
  • IQ score greater than 50 based on Wildland Test
  • Receiving risperidone therapy for at least one month
  • Lack of clear organic disease (based on family history and medical records) Clear organic causes include visual and hearing impairment, seizures, trauma cycles, chronic or acute medical disorder, and brain dysfunction.
  • Psychiatric disorders including Toure's syndrome, Fragile X syndrome, schizophrenia, Attension deficit hyperactivity disorder (ADHD) based on structured psychiatric interview conducted by pediatric psychiatrist

排除标准

  • If the parents do not cooperate for any reason after entering the study 2- 3-
  • Use of any psychotropic drugs other than risperidone
  • Any unbearable or life-threatening drug side effect or any other illness that requires medication which may interfere with results of this study.

研究者

发起方
Medical Science University of Mashhad

相似试验

Efficacy of N-Acetyl cysteine in patients with... | 临床试验